Latest Advances in Treating Menopause Symptoms

Menopause can bring uncomfortable symptoms such as hot flashes, night sweats, vaginal dryness, and sleep disturbances. Recent research has expanded both hormonal and non‑hormonal treatment options, making symptom control more effective and safer.

Hormone Therapy (HT)

Hormone therapy remains the most effective way to relieve vasomotor symptoms. A large 2013 study linked combined estrogen‑progestin therapy to higher risks of heart disease, cancer, and stroke, but a 2024 review found that initiating HT before age 60 in otherwise healthy women carries a lower risk profile.

The North American Menopause Society (now The Menopause Society) still recommends HT as first‑line treatment for moderate‑to‑severe hot flashes. Clinicians now tailor HT to the individual, considering age, cardiovascular risk, and personal preferences.

Key prescribing points:

• Avoid estrogen‑only therapy in women with an intact uterus; combine estrogen with a progestin.
• Prefer low‑dose regimens and limit duration to a few years when possible.
• Consider alternative routes—oral tablets, transdermal patches or gels, and vaginal creams, tablets, or rings—to reduce systemic exposure.

Bioidentical Hormone Therapy

Bioidentical hormones (e.g., estradiol, estriol) are plant‑derived compounds that mimic the body’s natural hormones. The FDA has not found evidence that they are safer than conventional HT, and many bioidentical products are not FDA‑regulated, which can affect quality and labeling.

A 2022 clinical trial showed that a simple, hormone‑free vaginal moisturizer performed as well as a low‑dose estriol cream for vaginal discomfort, suggesting that non‑hormonal options may be sufficient for some women.

If you prefer a bioidentical approach, discuss FDA‑approved estradiol formulations (usually combined with progesterone) with your provider.

Non‑Hormonal Options for Vasomotor Symptoms

Several medications are used off‑label to reduce hot flashes, including gabapentin, clonidine, and certain antidepressants (e.g., venlafaxine, escitalopram). These drugs have not received specific FDA approval for menopausal symptoms but are frequently prescribed based on clinical experience.

FDA‑Approved Non‑Hormonal Medications

• Fezolinetant (Veozah) – approved in 2023, this neurokinin‑3 receptor antagonist regulates body temperature and has been shown to decrease the frequency and severity of hot flashes.
• Paroxetine (Brisdelle) – an SSRI approved for vasomotor symptom relief, offering modest improvement with a favorable safety profile.

Managing Genitourinary Symptoms

Vaginal dryness, itching, pain during intercourse, and urinary urgency are common after menopause. Treatment options include:

• Local estrogen therapy (creams, tablets, or rings) to restore vaginal tissue health.
• Over‑the‑counter vaginal moisturizers and lubricants for daily comfort.
• FDA‑approved non‑hormonal agents for dyspareunia, such as ospemifene.
• Standard therapies for urinary infections and urgency, which are not menopause‑specific but can improve quality of life.

Other Emerging Treatments

A 2022 study reported that hair loss affects many post‑menopausal women. A 2019 trial demonstrated that a topical combination of minoxidil and finasteride increased hair density and thickness in this population.

Ongoing research continues to explore novel compounds and delivery methods to further expand the therapeutic toolkit.

Practical Tips

Keeping a symptom diary helps you and your clinician identify patterns and select the most appropriate therapy. Discuss all options—hormonal, bioidentical, and non‑hormonal—with your healthcare provider to create a personalized plan that balances effectiveness with safety.